| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biomarkers, Tumor | 12 | 2025 | 1660 | 0.770 |
Why?
|
| Carcinoma, Renal Cell | 5 | 2025 | 357 | 0.650 |
Why?
|
| Mutation | 9 | 2025 | 4265 | 0.540 |
Why?
|
| Kidney Neoplasms | 4 | 2025 | 531 | 0.520 |
Why?
|
| In Situ Hybridization, Fluorescence | 8 | 2024 | 360 | 0.450 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2019 | 538 | 0.400 |
Why?
|
| Receptor, ErbB-2 | 3 | 2024 | 280 | 0.400 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2025 | 453 | 0.350 |
Why?
|
| Hodgkin Disease | 2 | 2023 | 144 | 0.320 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2024 | 422 | 0.300 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2025 | 379 | 0.270 |
Why?
|
| Immunohistochemistry | 4 | 2024 | 1786 | 0.270 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2025 | 825 | 0.270 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2019 | 81 | 0.260 |
Why?
|
| Leiomyoma | 2 | 2022 | 211 | 0.260 |
Why?
|
| Glioma | 2 | 2019 | 298 | 0.240 |
Why?
|
| Pleural Neoplasms | 2 | 2019 | 200 | 0.230 |
Why?
|
| MAP Kinase Signaling System | 1 | 2025 | 200 | 0.210 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2025 | 177 | 0.200 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 2023 | 19 | 0.200 |
Why?
|
| Genes, myb | 1 | 2002 | 5 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 2002 | 7 | 0.190 |
Why?
|
| Brain Neoplasms | 2 | 2019 | 810 | 0.190 |
Why?
|
| Neurofibromin 2 | 1 | 2022 | 31 | 0.180 |
Why?
|
| Hematologic Diseases | 1 | 2022 | 77 | 0.180 |
Why?
|
| DNA Replication | 1 | 2002 | 168 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2025 | 2465 | 0.180 |
Why?
|
| Humans | 34 | 2025 | 93138 | 0.170 |
Why?
|
| Meningioma | 1 | 2022 | 62 | 0.170 |
Why?
|
| Meningeal Neoplasms | 1 | 2022 | 69 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2019 | 106 | 0.170 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2024 | 317 | 0.170 |
Why?
|
| Head and Neck Neoplasms | 2 | 2020 | 1071 | 0.170 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 627 | 0.170 |
Why?
|
| B7-H1 Antigen | 2 | 2023 | 305 | 0.170 |
Why?
|
| Graft vs Host Disease | 1 | 2023 | 365 | 0.160 |
Why?
|
| DNA Mutational Analysis | 2 | 2025 | 543 | 0.160 |
Why?
|
| Middle Aged | 15 | 2025 | 27539 | 0.160 |
Why?
|
| Cell Cycle Proteins | 1 | 2002 | 409 | 0.150 |
Why?
|
| STAT6 Transcription Factor | 1 | 2019 | 30 | 0.150 |
Why?
|
| Gene Rearrangement | 2 | 2019 | 168 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2020 | 33 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2020 | 33 | 0.150 |
Why?
|
| Aged, 80 and over | 8 | 2025 | 7039 | 0.150 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 2019 | 20 | 0.150 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2019 | 15 | 0.150 |
Why?
|
| Aged | 12 | 2025 | 20398 | 0.150 |
Why?
|
| Gene Duplication | 2 | 2012 | 128 | 0.150 |
Why?
|
| Adult | 14 | 2025 | 27850 | 0.150 |
Why?
|
| Germ-Line Mutation | 1 | 2022 | 381 | 0.140 |
Why?
|
| Osteosarcoma | 1 | 2020 | 156 | 0.140 |
Why?
|
| Stromal Cells | 1 | 2019 | 152 | 0.140 |
Why?
|
| Database Management Systems | 1 | 2018 | 44 | 0.140 |
Why?
|
| Pathology, Molecular | 1 | 2018 | 34 | 0.140 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2024 | 1073 | 0.130 |
Why?
|
| Female | 17 | 2025 | 48547 | 0.130 |
Why?
|
| Drosophila Proteins | 1 | 2002 | 521 | 0.130 |
Why?
|
| Medical Informatics | 1 | 2018 | 49 | 0.130 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 401 | 0.130 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2017 | 9 | 0.130 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2018 | 134 | 0.130 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2019 | 260 | 0.130 |
Why?
|
| Bone Neoplasms | 1 | 2020 | 308 | 0.130 |
Why?
|
| Pheochromocytoma | 1 | 2017 | 53 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2023 | 603 | 0.130 |
Why?
|
| Ovarian Neoplasms | 1 | 2023 | 795 | 0.130 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2017 | 83 | 0.120 |
Why?
|
| Male | 16 | 2025 | 44360 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2016 | 11 | 0.120 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 1231 | 0.120 |
Why?
|
| Trans-Activators | 1 | 2019 | 439 | 0.120 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2019 | 184 | 0.120 |
Why?
|
| Rhabdoid Tumor | 1 | 2016 | 21 | 0.120 |
Why?
|
| Monosomy | 1 | 2016 | 12 | 0.120 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2016 | 66 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 940 | 0.120 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2016 | 38 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2019 | 1339 | 0.120 |
Why?
|
| Receptor, ErbB-3 | 1 | 2016 | 18 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2016 | 83 | 0.120 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 537 | 0.120 |
Why?
|
| Urothelium | 1 | 2016 | 67 | 0.120 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 74 | 0.120 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2016 | 91 | 0.110 |
Why?
|
| Urologic Neoplasms | 1 | 2016 | 78 | 0.110 |
Why?
|
| Quinazolines | 1 | 2016 | 211 | 0.110 |
Why?
|
| Esophageal Neoplasms | 1 | 2017 | 343 | 0.110 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2018 | 663 | 0.110 |
Why?
|
| Leukemia | 1 | 2017 | 300 | 0.110 |
Why?
|
| Genomics | 2 | 2017 | 848 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 298 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 636 | 0.110 |
Why?
|
| Stomach Neoplasms | 1 | 2017 | 305 | 0.110 |
Why?
|
| Predictive Value of Tests | 4 | 2019 | 1704 | 0.100 |
Why?
|
| Neuroblastoma | 1 | 2017 | 394 | 0.100 |
Why?
|
| Mesothelioma | 1 | 2016 | 331 | 0.100 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 1 | 2012 | 6 | 0.100 |
Why?
|
| Precision Medicine | 1 | 2017 | 457 | 0.100 |
Why?
|
| Myopathies, Structural, Congenital | 1 | 2012 | 11 | 0.100 |
Why?
|
| Retrospective Studies | 6 | 2024 | 10132 | 0.090 |
Why?
|
| T-Lymphocytes | 1 | 2019 | 1276 | 0.090 |
Why?
|
| Young Adult | 5 | 2024 | 6922 | 0.090 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2011 | 40 | 0.090 |
Why?
|
| Adolescent | 5 | 2024 | 9550 | 0.090 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2011 | 41 | 0.090 |
Why?
|
| DNA Methylation | 1 | 2016 | 699 | 0.090 |
Why?
|
| Reproducibility of Results | 4 | 2019 | 2705 | 0.080 |
Why?
|
| Prognosis | 3 | 2025 | 3891 | 0.080 |
Why?
|
| Transcription Factors | 1 | 2018 | 1687 | 0.080 |
Why?
|
| Genetic Testing | 3 | 2022 | 564 | 0.080 |
Why?
|
| Biomarkers | 1 | 2016 | 1905 | 0.070 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 762 | 0.070 |
Why?
|
| Phenotype | 3 | 2019 | 2545 | 0.060 |
Why?
|
| NF-kappa B | 2 | 2019 | 408 | 0.060 |
Why?
|
| raf Kinases | 1 | 2025 | 15 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2025 | 50 | 0.060 |
Why?
|
| Karyotyping | 1 | 2025 | 220 | 0.060 |
Why?
|
| Clone Cells | 1 | 2025 | 219 | 0.060 |
Why?
|
| Intellectual Disability | 1 | 2006 | 196 | 0.060 |
Why?
|
| Infant, Newborn | 3 | 2016 | 2427 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 889 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 985 | 0.050 |
Why?
|
| GTP Phosphohydrolases | 1 | 2025 | 80 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1447 | 0.050 |
Why?
|
| Gene Amplification | 1 | 2024 | 139 | 0.050 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2025 | 162 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 2363 | 0.050 |
Why?
|
| Necrosis | 1 | 2023 | 203 | 0.050 |
Why?
|
| Salivary Glands | 1 | 2002 | 20 | 0.050 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2023 | 132 | 0.050 |
Why?
|
| S Phase | 1 | 2002 | 64 | 0.050 |
Why?
|
| G1 Phase | 1 | 2002 | 64 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 106 | 0.050 |
Why?
|
| Genes, Neurofibromatosis 2 | 1 | 2022 | 9 | 0.050 |
Why?
|
| Chickens | 1 | 2002 | 193 | 0.050 |
Why?
|
| Animals, Genetically Modified | 1 | 2002 | 186 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2025 | 3497 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2023 | 289 | 0.040 |
Why?
|
| Germ Cells | 1 | 2022 | 130 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2019 | 3044 | 0.040 |
Why?
|
| Genome, Human | 1 | 2006 | 823 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2023 | 4546 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2022 | 214 | 0.040 |
Why?
|
| Cell Division | 1 | 2002 | 689 | 0.040 |
Why?
|
| Papillomavirus Infections | 1 | 2024 | 301 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 1910 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2017 | 3781 | 0.040 |
Why?
|
| Recurrence | 1 | 2023 | 1188 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2022 | 753 | 0.040 |
Why?
|
| Tokyo | 1 | 2019 | 3 | 0.040 |
Why?
|
| France | 1 | 2019 | 52 | 0.040 |
Why?
|
| Face | 1 | 2020 | 108 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2022 | 752 | 0.040 |
Why?
|
| North America | 1 | 2019 | 197 | 0.040 |
Why?
|
| Mice | 2 | 2023 | 12230 | 0.040 |
Why?
|
| Carbonic Anhydrase II | 1 | 2018 | 4 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2025 | 1260 | 0.040 |
Why?
|
| Gene Dosage | 2 | 2011 | 211 | 0.030 |
Why?
|
| Transcription Factor RelA | 1 | 2018 | 39 | 0.030 |
Why?
|
| Gene Expression | 1 | 2002 | 1304 | 0.030 |
Why?
|
| Infant | 2 | 2017 | 3156 | 0.030 |
Why?
|
| Skull | 1 | 2020 | 267 | 0.030 |
Why?
|
| Observer Variation | 1 | 2019 | 570 | 0.030 |
Why?
|
| Drosophila melanogaster | 1 | 2002 | 629 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 105 | 0.030 |
Why?
|
| Risk Factors | 2 | 2019 | 5901 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2018 | 190 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2016 | 21 | 0.030 |
Why?
|
| Child | 2 | 2019 | 7273 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2016 | 39 | 0.030 |
Why?
|
| Receptors, Androgen | 1 | 2017 | 120 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 526 | 0.030 |
Why?
|
| Gene Fusion | 1 | 2016 | 40 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 1171 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 134 | 0.030 |
Why?
|
| Benchmarking | 1 | 2016 | 80 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2017 | 195 | 0.030 |
Why?
|
| Reference Standards | 1 | 2016 | 145 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1519 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 192 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2017 | 412 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 2016 | 245 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2018 | 958 | 0.030 |
Why?
|
| Acute Disease | 1 | 2017 | 838 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 1945 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 1518 | 0.030 |
Why?
|
| Chicago | 1 | 2019 | 1452 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2016 | 700 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 888 | 0.030 |
Why?
|
| Animals | 2 | 2023 | 27973 | 0.020 |
Why?
|
| Biopsy | 1 | 2016 | 1172 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 2757 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2012 | 292 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1926 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2018 | 1611 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2024 | 9074 | 0.020 |
Why?
|
| United States | 1 | 2024 | 7581 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 1171 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2011 | 469 | 0.020 |
Why?
|
| Time Factors | 1 | 2019 | 5380 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 3815 | 0.020 |
Why?
|
| Chromosome Breakage | 1 | 2006 | 16 | 0.020 |
Why?
|
| Physical Chromosome Mapping | 1 | 2006 | 26 | 0.020 |
Why?
|
| Chromosomes, Artificial, Bacterial | 1 | 2006 | 32 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2006 | 194 | 0.020 |
Why?
|
| Mosaicism | 1 | 2006 | 73 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2006 | 108 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 2006 | 213 | 0.010 |
Why?
|
| Heterozygote | 1 | 2006 | 381 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 691 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 826 | 0.010 |
Why?
|
| Neoplasms | 1 | 2016 | 3168 | 0.010 |
Why?
|